RxDoctor Payments Data

Knell Villarta, PA

Pain Medicine · Washington, DCNPI 1700560968

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,446 of the $7,513 with a category attached, or 72.5%. 15 manufacturers reported payments, led by Medtronic at 33.9% of the total.

$7,513in general payments, 2019–2025

Across 86 payments — averaging $87.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Nalu Medical, Inc.$2K
  • Boston Scientific$1K
  • Saluda Medical Americas, Inc.$1K
  • SPR Therapeutics, Inc$179
  • Nevro Corp.$170
  • plus $668 from 9 others

What the payments were for

  • Travel & lodging$2,02127%
  • Food & beverage$5,44672%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pain medicine providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$2,971
Medicare patients
20
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl74$72,147
PercocetOxycodone Hcl/Acetaminophen15$69,444
Xtampza ErOxycodone Myristate91$51,870
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen549$13,485
LinzessLinaclotide14$12,968
MovantikNaloxegol Oxalate21$8,677
Oxycodone Hcl382$8,006
Lidocaine88$7,625
Pregabalin195$5,044
Gabapentin283$4,910
Tizanidine Hcl404$4,856
Hydromorphone ErHydromorphone Hcl15$4,325
Fentanyl65$4,255
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen206$3,691
Hydromorphone Hcl92$3,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$41$51,87091 claims
AbbVieLinzess$62$12,96814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pain medicine providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.

Other pain medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →